PolbionicaS.A.
Research and experimental development in natural sciences and engineering
Overview
Polbionica is a leader in 3D bioprinting, developing the world's first functional bionic pancreas made from living cells that can produce insulin and glucagon. The company provides proprietary bioprinting materials, such as TintBionic® and Printiss®, and operates the ResearchLine™ bioreactor for tissue and organ cultivation. Their innovations aim to revolutionize the treatment of chronic diseases, particularly diabetes.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
The Polish-Swiss Forum for Health Dialogue
How to bridge the gap between researchers and entrepreneurs – key question 11. edition of the Polish-Swiss Forum of Dialogue for Health
European Commission Certificate awarded to Polbionica
Nasza innowacja jest chroniona patentem europejskim EP19461559, obejmującym kompleksową procedurę przygotowania bionicznej trzustki, począwszy od przygotowania ECM, który jest podstawą produkowanych bioszkieletów (biotusz A i B) do całego narządu z układem naczyniowym.
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-06-01. Active
28 1240 6973 1111 0011 0736 1865- 11 1240 6973 1111 0011 0886 7805
- 47 1240 5934 1978 0011 0311 7501
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 31, 2025 | Transformation registered |
Public aid
8 public aid cases recorded, with a total value of $4,229,621.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 23, 2025 | Aid for research and development projects: industrial research | — | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jul 23, 2025 | Aid for research and development projects: experimental development | — | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 19, 2025 | Aid for projects awarded a Seal of Excellence quality label | — | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-01-01 | Biodrukowana bioniczna trzustka 3D jako terapia na cukrzycę typu 1 | $2,610,623 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2021-07-01 | 3D biodrukowana tkanka wątrobowa wraz z układem naczyniowym jako innowacyjny model do oceny toksyczności leków i skuteczności terapii antynowotworowych | $2,271,472 | Program Operacyjny Inteligentny Rozwój | |
| 2020-06-01 | Przygotowanie wniosku do programu Horyzont 2020-Accelerator w celu rozwoju unikalnej technologii druku-3D bionicznej trzustki. | $15,129 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a management board consisting of two or more persons, joint action by two members of the management board is required to make declarations of will on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Michał Dawid Kiciński (52)  | Shareholder of a joint-stock company, 39.21% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| BioceltixS.A. | $616,315.97 | bioceltix.com | |
| OrthogetS.A. | $532,980.53 | orthoget.com | |
| Real ResearchS.A. | $443,579.51 | real-research.com | |
| Urbicumsp. z o.o. | $387,769.33 | urbicum.com | |
| BiottsS.A. | $372,115.60 | biotts.com | |
| MedisensonicS.A. | $362,572.63 | medisensonic.com | |
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | |
| BiocamS.A. | $327,799.68 | biocam.ai | |
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | |
| NanosanguisS.A. | $192,701.50 | nanosanguis.com |
Change history
| Date | Event |
|---|---|
| 2025-10-08 | Share capital change (540,000.00 PLN → 546,669.00 PLN) |
| 2025-08-13 | Address change (Aleja Prymasa Tysiąclecia 79a, 01-242, Warszawa → Ul. Nowy Kisielin-A. Wysockiego 1, 66-002, Zielona Góra) |
| 2025-01-21 | Entered in the register |
FAQ
Last updated: 2026-09-08